Chief Strategy Officer · BridgeBio Pharma, Inc. (BBIO)

Cameron Turtle

FY2020 is the first fiscal year CompBrief holds for Cameron Turtle as a named executive officer of BridgeBio Pharma; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$4,561,482

Salary $400,000Stock awards $3,940,081Bonus $210,000

4th of 6 named executive officers at BridgeBio Pharma by FY2020 total.

6 named officers on file for BridgeBio Pharma, FY2020

Cameron Turtle’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 2 equity grants, each cited to its filing
  • BBIO’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how BridgeBio Pharma’s whole pay program stands against its peers

  • BridgeBio Pharma’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on BBIO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 30, 2021 (DEF 14A).

Free

Get Cameron Turtle’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Cameron Turtle compensation by year

BridgeBio Pharma Summary Compensation Table · the one fiscal year held
In US dollars, as BridgeBio Pharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020
Salary$400,000
Bonus$210,000
Stock awards$3,940,081
Option awards$0
Non-equity incentive$0
Pension and deferred compensation$0
All other$11,400
Total$4,561,482

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BridgeBio Pharma, Inc. DEF 14A filed April 30, 2021, accession 0001193125-21-145491, and prior-year filings.

How this page was built: the BridgeBio Pharma, Inc. filed document, accession 0001193125-21-145491. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2021.

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
RSU5,249$373,256—
RSU786$55,892—
Option187,500—$17.00

Per the Outstanding Equity Awards at Fiscal Year-End table in BridgeBio Pharma, Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

BridgeBio Pharma’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Neil KumarChief Executive Officer$10,054,909
Michael HendersonChief Business Officer$7,991,241
Brian StolzChief Operating Officer$5,240,851
Cameron Turtle · this pageChief Strategy Officer$4,561,482
Brian StephensonChief Financial Officer$4,163,933
Charles HomcyChairman of Pharmaceuticals$1,855,805

The full BridgeBio Pharma compensation record

free company brief

This page is one person within BridgeBio Pharma's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are BridgeBio Pharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Cameron Turtle's compensation dossier · One-time report. No refunds.